{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:06:50Z","timestamp":1793390810072,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jpurol.2023.08.015","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:32:57Z","timestamp":1692415977000},"page":"753.e1-753.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-052X","authenticated-orcid":false,"given":"Felice E.E.","family":"van Veen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martje","family":"Schotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-4311","authenticated-orcid":false,"given":"Lisette A.","family":"\u2019t Hoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-7395","authenticated-orcid":false,"given":"Bertil F.M.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen R.","family":"Scheepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpurol.2023.08.015_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/nau.24211","article-title":"EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment","volume":"39","author":"Stein","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.jpurol.2023.08.015_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"issue":"3\u20134","key":"10.1016\/j.jpurol.2023.08.015_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5489\/cuaj.3527","article-title":"Anticholinergic use in children: persistence and patterns of therapy","volume":"10","author":"Blais","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"7","key":"10.1016\/j.jpurol.2023.08.015_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1464-410x.2001.02152.x","article-title":"Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida","volume":"87","author":"Ferrara","year":"2001","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.jpurol.2023.08.015_bib5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11934-014-0444-z","article-title":"The evaluation and management of refractory neurogenic overactive bladder","volume":"15","author":"Kurpad","year":"2014","journal-title":"Curr Urol Rep"},{"issue":"2","key":"10.1016\/j.jpurol.2023.08.015_bib6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/nau.24248","article-title":"EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management","volume":"39","author":"Stein","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"10.1016\/j.jpurol.2023.08.015_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.jpurol.2023.08.015_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sc.2015.195","article-title":"Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury","volume":"54","author":"Wollner","year":"2016","journal-title":"Spinal Cord"},{"issue":"1","key":"10.1016\/j.jpurol.2023.08.015_bib9","first-page":"7","article-title":"[Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation]","volume":"61","author":"Wada","year":"2015","journal-title":"Hinyokika Kiyo"},{"issue":"4","key":"10.1016\/j.jpurol.2023.08.015_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-021-00452-4","article-title":"Mirabegron: pediatric first approval","volume":"23","author":"Keam","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"8","key":"10.1016\/j.jpurol.2023.08.015_bib11","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","article-title":"Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study","volume":"37","author":"Park","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2023.08.015_bib12","doi-asserted-by":"crossref","first-page":"655 e1","DOI":"10.1016\/j.jpurol.2020.07.020","article-title":"Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction","volume":"16","author":"Sager","year":"2020","journal-title":"J Pediatr Urol"},{"issue":"6","key":"10.1016\/j.jpurol.2023.08.015_bib13","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/nau.24657","article-title":"Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study","volume":"40","author":"Baka-Ostrowska","year":"2021","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"10.1016\/j.jpurol.2023.08.015_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/nau.22783","article-title":"International Children's Continence Society Standardization S. International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children","volume":"34","author":"Bauer","year":"2015","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.jpurol.2023.08.015_bib15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/nau.21129","article-title":"Bladder compliance what does it represent: can we measure it, and is it clinically relevant?","volume":"30","author":"Wyndaele","year":"2011","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.jpurol.2023.08.015_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/nau.23124","article-title":"International continence society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study","volume":"36","author":"Rosier","year":"2017","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"10.1016\/j.jpurol.2023.08.015_bib17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0022-5347(05)67730-0","article-title":"Differences in bladder compliance with time and associations of bladder management with compliance in spinal cord injured patients","volume":"163","author":"Weld","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.jpurol.2023.08.015_bib18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/nau.24928","article-title":"The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis","volume":"41","author":"Yuanzhuo","year":"2022","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.jpurol.2023.08.015_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.jpurol.2023.08.015_bib20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/eurheartj\/ehx366","article-title":"Cardiac myocyte beta3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling","volume":"39","author":"Hermida","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpurol.2023.08.015_bib21","article-title":"The efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpurol.2023.08.015_bib22","first-page":"187","article-title":"Real-world effects of mirabegron in patients with chronic neurogenic detrusor overactivity - a retrospective cohort study","volume":"12","author":"Krebs","year":"2020","journal-title":"Res Rep Urol"},{"issue":"7","key":"10.1016\/j.jpurol.2023.08.015_bib23","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513123003303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513123003303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:53:58Z","timestamp":1761486838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513123003303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1477513123003303"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2023.08.015","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2023.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company.","name":"copyright","label":"Copyright"}]}}